Search Results - "Atzpodien, J"

Metastatic renal carcinoma comprehensive prognostic system by ATZPODIEN, J, ROYSTON, P, WANDERT, T, REITZ, M

“…The purpose of the study was to identify a comprehensive prognostic system of pretreatment clinical parameters in 425 patients (pts) with metastatic renal-cell…”
Get full text

A nine-gene signature predicting clinical outcome in cutaneous melanoma by Brunner, G., Reitz, M., Heinecke, A., Lippold, A., Berking, C., Suter, L., Atzpodien, J.

“…Purpose Current histopathological staging of cutaneous melanoma is limited in predicting outcome, and complementary molecular markers are not available for…”
Get full text

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by ATZPODIEN, J, KIRCHNER, H, BODENSTEIN, H, POMER, S, METZNER, B, REBMANN, U, OBERNEDER, R, SIEBELS, M, WANDERT, T, PUCHBERGER, T, REITZ, M, JONAS, U, BERGMANN, L, SCHOTT, H, HEYNEMANN, H, FORNARA, P, LOENING, S. A, ROIGAS, J, MÜLLER, S. C

“…We conducted a prospectively randomized clinical trial to compare the efficacy of three outpatient therapy regimens in 341 patients with progressive metastatic…”
Get full text

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109) by Kurreck, A., Geissler, M., Martens, U. M., Riera-Knorrenschild, J., Greeve, J., Florschütz, A., Wessendorf, S., Ettrich, T., Kanzler, S., Nörenberg, D., Seidensticker, M., Held, S., Buechner-Steudel, P., Atzpodien, J., Heinemann, V., Stintzing, S., Seufferlein, T., Tannapfel, A., Reinacher-Schick, A. C., Modest, D. P.

“…Purpose In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and…”
Get full text

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by ATZPODIEN, J, SCHMITT, E, WANDERT, T, REITZ, M, GERTENBACH, U, FORNARA, P, HEYNEMANN, H, MASKOW, A, ECKE, M, WÖLTJEN, H. H, JENTSCH, H, WIELAND, W

“…We conducted a prospectively randomised clinical trial to investigate the role of adjuvant outpatient immunochemotherapy administered postoperatively in…”
Get full text

CXCR4/CXCL12 expression and signalling in kidney cancer by SCHRADER, A. J, LECHNER, O, ATZPODIEN, J, BUER, J, LAUBER, J, TEMPLIN, M, DITTMAR, K. E. J, MACHTENS, S, MENGEL, M, PROBST-KEPPER, M, FRANZKE, A, WOLLENSAK, T, GATZLAFF, P

“…CXCL12 (SDF-1), a CXC-chemokine, and its specific receptor, CXCR4, have recently been shown to be involved in tumourgenesis, proliferation and angiogenesis…”
Get full text

2049 AIO-KRK-0109: A randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC) by Martens, U.M, Wessendorf, S, Knorrenschild, J. Riera, Buechner-Steudel, P, Florschuetz, A, Atzpodien, J, Greeve, J, Kanzler, S, Ettrich, T, Lindig, U, Egger, M, Hebart, H, Geissler, M

Get full text

An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma by ROYSTON, P, REITZ, M, ATZPODIEN, J

“…We present a prognostic model for metastatic renal cell carcinoma based on fractional polynomials. We retrospectively analysed 425 metastatic renal cell…”
Get full text

IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma : long-term results of a controlled randomized clinical trial by ATZPODIEN, J, KIRCHNER, H, PATZELT, T, REITZ, M, ILLIGER, H. J, METZNER, B, UKENA, D, SCHOTT, H, FUNKE, P. J, GRAMATZKI, M, VON JÜRGENSON, S, WANDERT, T

“…We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-alpha2a, subcutaneous interleukin-2 and…”
Get full text

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients by ATZPODIEN, J, TERFLOTH, K, FLUCK, M, REITZ, M

“…To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma…”
Get full text

Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM) by ATZPODIEN, J, NEUBER, K, PAUL, E, PATZELT, T, REITZ, M, KAMANABROU, D, FLUCK, M, BRÖCKER, E. B, NEUMANN, C, RÜNGER, T. M, SCHULER, G, VON DEN DRIESCH, P, MÜLLER, I

“…The purpose of this randomized trial was to evaluate the efficacy of combination chemoimmunotherapy compared with chemotherapy alone. A total of 124 patients…”
Get full text

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome by ATZPODIEN, J, KÜCHLER, Th, WANDERT, T, REITZ, M

“…We conducted a prospective quality-of-life analysis during outpatient immunotherapy in 22 patients with progressive metastatic renal cell carcinoma (RCC)…”
Get full text

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by Atzpodien, J, Kirchner, H, Rebmann, U, Soder, M, Gertenbach, U, Siebels, M, Roigas, J, Raschke, R, Salm, S, Schwindl, B, Müller, S C, Hauser, S, Leiber, C, Huland, E, Heinzer, H, Siemer, S, Metzner, B, Heynemann, H, Fornara, P, Reitz, M

“…We performed a prospectively randomised clinical trial to compare the efficacy of four subcutaneous interleukin-2-(sc-IL-2) and sc interferon- α 2a (sc-IFN- α…”
Get full text

Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma by Atzpodien, J., Wandert, T., Reitz, M.

“…Based on the increasing proportion of elderly cancer patients, we compared the efficacy of subcutaneous cytokine based home therapy in older (age ≥ 60 years)…”
Get full text

Interleukin-2/interferon- alpha 2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) by Atzpodien, J, Kirchner, H, Rebmann, U, Soder, M, Gertenbach, U, Siebels, M, Roigas, J, Raschke, R, Salm, S, Schwindl, B, Mueller, S C, Hauser, S, Leiber, C, Huland, E

“…We performed a prospectively randomised clinical trial to compare the efficacy of four subcutaneous interleukin-2-(sc-IL-2) and sc interferon- alpha 2a…”
Get full text

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma by WITTKE, F, HOFFMANN, R, BUER, J, DALLMANN, I, OEVERMANN, K, SEL, S, WANDERT, T, GANSER, A, ATZPODIEN, J

“…Interleukin 10 (IL-10) is an immunosuppressive factor and has been detected in tumour cell cultures of renal cell carcinoma and of malignant melanoma. IL-10…”
Get full text

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas : results of a phase-II study of the German low-grade lymphoma study group by FEURING-BUSKE, M, KNEBA, M, HALLEK, M, AULITZKY, E, HIDDEMANN, W, UNTERHALT, M, ENGERT, A, GRAMATZKI, M, HILLER, E, TRÜMPER, L, BRUGGER, W, OSTERMANN, H, ATZPODIEN, J

“…The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma. The…”
Get full text

Peripheral Blood Tyrosinase Messenger RNA Detection and Survival in Malignant Melanoma by Kunter, Uta, Buer, Jan, Probst, Michael, Duensing, Stefan, Dallmann, Iris, Grosse, Jens, Kirchner, Hartmut, Schluepen, Eva Maria, Volkenandt, Matthias, Ganser, Arnold, Atzpodien, Jens

“…Background: The most widely accepted criteria for the evaluation of prognosis of malignant melanoma are histopathologic and clinical presentation. No currently…”
Get full text

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma by Franzke, A, Probst-Kepper, M, Buer, J, Duensing, S, Hoffmann, R, Wittke, F, Volkenandt, M, Ganser, A, Atzpodien, J

“…Very rapid progression of disease with a median survival of 6-9 months is a common feature of metastatic cutaneous malignant melanoma. Nevertheless,…”
Get full text

Capecitabine in the treatment of metastatic renal cell carcinoma by OEVERMANN, K, BUER, J, HOFFMANN, R, FRANZKE, A, SCHRADER, A, PATZELT, T, KIRCHNER, H, ATZPODIEN, J

“…To evaluate the therapeutic effects and systemic toxicities of a capecitabine-based home therapy regimen in patients with metastatic renal cell carcinoma, 30…”
Get full text